Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ENPP1 | P22413 | 7/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11711194 | 0.80 | ALDH1A1 (0.47) | ALDH1A1HSD17B10ENPP1L3MBTL1LMNA | |
| SCHEMBL10627753 | 0.79 | ALDH1A1 (0.41) | ALDH1A1HSD17B10ENPP1L3MBTL1LMNA | |
| SCHEMBL11709557 | 0.78 | ALDH1A1 (0.45) | ALDH1A1HSD17B10ENPP1L3MBTL1LMNA | |
| SCHEMBL5674713 | 0.78 | ALDH1A1 (0.47) | ALDH1A1HSD17B10ENPP1L3MBTL1LMNA | |
| SCHEMBL7819692 | 0.78 | TSHR (0.50) | ALDH1A1HSD17B10ENPP1LMNAKMT2A | |
| SCHEMBL24127885 | 0.76 | ENPP1 (0.59) | ALDH1A1ENPP1L3MBTL1LMNAGAA | |
| SCHEMBL20482747 | 0.75 | ALDH1A1 (0.46) | ALDH1A1HSD17B10ENPP1L3MBTL1LMNA | |
| SCHEMBL7117782 | 0.75 | ALDH1A1 (0.44) | ALDH1A1HSD17B10ENPP1L3MBTL1LMNA | |
| SCHEMBL21222988 | 0.74 | MBOAT4 (0.56) | — | |
| SCHEMBL24127923 | 0.74 | ENPP1 (0.57) | ALDH1A1ENPP1L3MBTL1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289523-A1 | PYRROLO [3,2-E] [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINES DERIVATIVES AS INHIBITORS OF MICROGLIA ACTIVATION | BTG INTERNATIONAL LIMITED (GB) | 2012-11-15 | — | — | US | disclosed |
| US-20120289524-A1 | PYRROLO [3,2-E] [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINES DERIVATIVES AS INHIBITORS OF MICROGLIA ACTIVATION | SENEXIS LIMITED (GB) | 2012-11-15 | — | — | US | disclosed |
| US-20120289523-A1 | PYRROLO [3,2-E] [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINES DERIVATIVES AS INHIBITORS OF MICROGLIA ACTIVATION | BTG INTERNATIONAL LIMITED (GB) | 2012-11-15 | — | — | US | disclosed |
| US-20120289524-A1 | PYRROLO [3,2-E] [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINES DERIVATIVES AS INHIBITORS OF MICROGLIA ACTIVATION | SENEXIS LIMITED (GB) | 2012-11-15 | — | — | US | disclosed |
| US-20120289523-A1 | PYRROLO [3,2-E] [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINES DERIVATIVES AS INHIBITORS OF MICROGLIA ACTIVATION | BTG INTERNATIONAL LIMITED (GB) | 2012-11-15 | — | — | US | disclosed |
| US-20120289524-A1 | PYRROLO [3,2-E] [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINES DERIVATIVES AS INHIBITORS OF MICROGLIA ACTIVATION | SENEXIS LIMITED (GB) | 2012-11-15 | — | — | US | disclosed |
| EP-2488528-A1 | PYRROLO [3,2 -E][1,2,4]TRIAZOLO [1,5-A]PYRIMIDINES DERIVATIVES AS INHIBITORS OF MICROGLIA ACTIVATION | Senexis Limited (GB) | 2012-08-22 | — | — | EP | disclosed |
| EP-2488527-A1 | PYRROLO [3, 2 -E][1,2,4]TRIAZOLO [1,5 -A]PYRIMIDINES DERIVATIVES AS INHIBITORS OF MICROGLIA ACTIVATION | Senexis Limited (GB) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011042496-A1 | PYRROLO [3, 2 -E] [1,2,4] TRIAZOLO [1,5 -A] PYRIMIDINES DERIVATIVES AS INHIBITORS OF MICROGLIA ACTIVATION | SENEXIS LIMITED (GB) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011042496-A1 | PYRROLO [3, 2 -E] [1,2,4] TRIAZOLO [1,5 -A] PYRIMIDINES DERIVATIVES AS INHIBITORS OF MICROGLIA ACTIVATION | SENEXIS LIMITED (GB) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011042497-A1 | PYRROLO [3,2 -E] [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINES DERIVATIVES AS INHIBITORS OF MICROGLIA ACTIVATION | SENEXIS LIMITED (GB) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011042497-A1 | PYRROLO [3,2 -E] [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINES DERIVATIVES AS INHIBITORS OF MICROGLIA ACTIVATION | SENEXIS LIMITED (GB) | 2011-04-14 | — | — | WO | disclosed |
| EP-0101517-B1 | NOVEL S-TRIAZOLE(1,5-A)PYRIMIDINE DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-29 | — | — | EP | disclosed |
| EP-0101517-A1 | NOVEL s-TRIAZOLE(1,5-a)PYRIMIDINE DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1984-02-29 | — | — | EP | disclosed |
| US-4007189-A | VASODILATION, HYPOTENSIVE | SANKYO COMPANY LIMITED (JA) | 1977-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289524-A1 | PYRROLO [3,2-E] [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINES DERIVATIVES AS INHIBITORS OF MICROGLIA ACTIVATION | CX3CR1, CSF1R, P2RX1 | ALDH1A1 873/4885HSD17B10 4326/4885ENPP1 824/4885 |
| US-20120289523-A1 | PYRROLO [3,2-E] [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINES DERIVATIVES AS INHIBITORS OF MICROGLIA ACTIVATION | CX3CR1, CSF1R, PSEN1 | ALDH1A1 1002/4885HSD17B10 4441/4885ENPP1 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.